What is Verrica's gross profit margin?

What is the market's earnings forecast for Verrica next quarter?

What is Verrica's latest dividend and current dividend yield?

What were the key takeaways from Verrica's earnings call?

What factors drove the changes in Verrica's revenue and profit?

What guidance did Verrica's management provide for the next earnings period?

What were the key takeaways from Verrica’s earnings call?

What is the revenue and EPS growth rate for Verrica year over year?

- **Revenue Surge**: YCANTH revenue up 130% YoY in 2025, with Q4 2025 dispensed units up 58% YoY and February 2026 at record highs.
- **Pipeline Momentum**: Phase III for YCANTH in common warts dosed first patient in Q4 2025; VP-315 Phase III design aligned with FDA, targeting 2026启动.
- **Financial Resilience**: $50M equity raise extended cash runway to 2027, with $30.1M cash as of Q4 2025 and debt fully retired.
- **Global Expansion**: YCANTH launched in Japan (February 2026) and progressing toward EU approval, with CHMP positive feedback in 2025.
- **Cost Efficiency**: SG&A down 40% YoY, R&D expenses down 21% YoY, supporting disciplined growth strategy.

**【CEO Summary Section】**
- **Revenue Growth**: YCANTH revenue grew 130% YoY in 2025, driven by a new commercial strategy and cost reductions (40% decrease in SG&A). Q4 2025 YCANTH dispensed units reached 13,654, up 58% YoY, with February 2026 showing a record high.
- **Pipeline Progress**: Phase III for YCANTH in common warts (dosed first patient in Q4 2025) and VP-315 for basal cell carcinoma (Phase III design aligned with FDA). Torii contributed $18M in milestones and $40M in program costs.
- **Financial Strength**: $50M equity raise in Q4 2025 extended cash runway to 2027, with $30.1M cash as of Q4 2025. Debt fully retired in November 2025.
- **Global Expansion**: YCANTH launched in Japan (February 2026) and progressing toward EU approval, with CHMP positive feedback in 2025.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Total revenue $5.1M (vs. $0.3M in 2024), including $3.7M YCANTH and $1.4M Torii collaboration. Full-year 2025 revenue $35.6M (vs. $7.6M in 2024), with 85.7% gross product margin.
- **Cost Management**: R&D expenses $8.9M (down 21% YoY), SG&A $35.2M (down 36% YoY). Loss on extinguishment of debt $1.5M, offset by $1.8M derivative gain.
- **Liquidity**: $30.1M cash as of Q4 2025, supporting operations into 2027.

**【Q&A Highlights】**
- **YCANTH Rx**: New non-dispensing pharmacy launched Q4 2025 to streamline prescriptions, with early traction in reducing administrative barriers.
- **Salesforce Expansion**: Targeting 50 reps by 2026, focusing on dermatologists and pediatricians to leverage existing prescriber relationships.
- **Common Warts Program**: Phase III enrollment underway, with potential for 2026 data readouts. VP-315 Phase III design finalized, seeking nondilutive funding.
- **Competitive Dynamics**: YCANTH's efficacy and safety profile differentiate it from competitors, with 97% response rate in basal cell trials.
- **Japan and EU Strategy**: Japan launch in February 2026, with EU MA application preparation underway, exploring partnerships for broader access.

Verrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call Transcript

- **YCANTH Growth Accelerates**: Q2 2025 dispensed units up 32.8% QoQ to 13,434, driven by focused commercial strategy and $25 co-pay program.
- **Torii Partnership Boosts Cash Flow**: $8 million milestone received, with potential $10 million upon Japanese approval, supporting global Phase III launch in Q4 2025.
- **Financial Health Improves**: GAAP net income turns positive ($0.2 million) vs. $17.2 million loss in Q2 2024; cash balance $15.4 million with $25M warrant upside.
- **Pipeline Momentum**: VP-315 Phase III planning underway; FDA-endorsed trial design and partner discussions for funding.

**【CEO Opening Remarks】**
- Q2 2025 YCANTH dispensed applicator units reached 13,434, up 32.8% sequentially, driven by a focused commercial strategy targeting high-prevalence markets.
- Received $8 million milestone payment from Torii Pharmaceutical for the global Phase III program for common warts, with potential additional $10 million upon Japanese approval.
- VP-315 Phase III planning underway for basal cell carcinoma, with FDA-endorsed trial design and partner discussions for funding.

**【CFO Financial Commentary】**
- Total Q2 2025 revenue: $12.7 million (vs. $5.2 million in Q2 2024), including $8 million from Torii and $4.5 million in YCANTH net revenue.
- GAAP net income: $0.2 million ($0.02/share) vs. $17.2 million loss in Q2 2024. Non-GAAP net income: $2.4 million ($0.25/share).
- R&D expenses down 42% YoY to $1.8 million; SG&A down 47% YoY to $8.9 million, reflecting cost optimization.
- Cash balance: $15.4 million as of June 30, 2025, with potential $25 million from warrant exercises by November 2025.

**【Q&A Highlights】**
- **Sales Force Expansion**: Maintaining ~35 reps with 5-10 additional hires planned, focusing on high-impact territories.
- **Growth Drivers**: Improved access via co-pay program ($25 max per treatment), expanded pharmacy network, and clinician trust in YCANTH's safety/efficacy.
- **YCANTH vs. Compounded Cantharidin**: YCANTH adoption growing for molluscum, while compounded cantharidin used for warts due to regulatory status.
- ** Medicaid/Commercial Coverage**: >90% pediatric Medicaid coverage; expanding commercial access with 70%+ of dermatologists now covered.
- **Receivables & GTN**: Sequential increase due to 60-day collection terms; no change to WACC, but co-pay program use may impact future GTN.


Verrica Pharmaceuticals Inc. (VRCA) Q2 2025 Earnings Call Transcript

- **Revenue Growth Accelerates**: Q1 2025 YCANTH revenue up 17% QoQ to $3.4M, driven by 16.7% unit growth.
- **Cost Efficiency Drives Margin Expansion**: Q1 2025 R&D/SameG&A down 52%/46% YoY, gross margin 88%.
- **Clinical Pipeline Momentum**: $8M Phase III milestone potential; VP-315 Phase II shows 97% ORR in basal cell carcinoma.
- **Cash Position Critical**: $29.6M cash needs $8M milestone or warrant exercise to fund 12-month operations.
- **Seasonal Growth Strategy**: Targeted summer marketing to capitalize on expected patient increase.

**【CEO Opening Remarks】**
- YCANTH dispensed applicator units grew 16.7% QoQ to over 10,000 units, driving $3.4M revenue in Q1 2025.
- Commercial strategy focuses on high-prevalence territories with strong insurance coverage, resulting in normalized distributor inventory levels.
- Clinical pipeline progress: Phase III common warts trial with Torii (Japan) could begin mid-2025, with $8M milestone payment potential. VP-315 Phase II data shows 97% ORR in basal cell carcinoma.
- Cost-cutting measures reduced Q1 expenses, enabling selective sales force expansion in high-demand markets.

**【CFO Financial Highlights】**
- Q1 2025 total revenue: $3.4M (all YCANTH), up from $2.9M in Q4 2024.
- Gross product margin: 88%, with $0.4M cost of goods sold.
- R&D expenses: $2.3M (-52% YoY), SG&A: $8.8M (-46% YoY).
- GAAP net loss: $9.7M (-52% YoY), Non-GAAP net loss: $7.8M (-56% YoY).
- Cash balance: $29.6M as of March 31, 2025. Potential $8M milestone from Torii Phase III trial or $25M from warrant exercises needed for 12-month cash runway.

**【Q&A Key Takeaways】**
- **Pediatrician vs. Dermatologist Split**: Both segments growing, with pediatricians increasingly adopting YCANTH.
- **Summer Seasonality**: Anticipated patient increase through targeted marketing; no significant inventory pull-through delays expected.
- **Full Year 2025 Outlook**: No formal guidance, but Q1 trend of 16.7% QoQ growth suggests accelerating momentum. Dispensed units and revenue alignment improving.
- **Gross-to-Net Adjustments**: Stable at ~12%, reflecting normalized distributor ordering patterns.
- **Sales Force Stability**: Low turnover among core performers; cautious expansion based on demand signals.

Verrica Pharmaceuticals (VRCA)-13 May 25-2025 Q1 Earnings call transcript

- **Commercial Turnaround Success**: 50% cost reduction achieved with YCANTH dispensed units up 44.8% YoY to 8,654 in Q4. 
- **Pipeline Breakthroughs**: VP-315 shows 97% response rate in BCC; Torii NDA filed for Japan YCANTH. 
- **Financial Resilience**: $42M equity raise stabilizes cash at $46.3M; covenant waivers secure through Q1 2025. 
- **Growth Catalysts**: Common warts Phase III trial in Japan (mid-2025) with no incremental Verrica costs. 


**【CEO Opening Remarks】**
- **Turnaround Progress**: Reduced operating expenses by 50% through commercial realignment, achieving sequential growth in YCANTH dispensed units (12.3% QoQ to 8,654 units in Q4 2024). 
- **YCANTH Expansion**: Introduced single-applicator configuration to reduce physician acquisition costs and expanded specialty pharmacy access. Distributor inventory stabilized at normalized levels. 
- **Pipeline Momentum**: 
  - Common warts Phase III trial in Japan (expected mid-2025 start) with Torii covering Verrica's costs. 
  - VP-315 for basal cell carcinoma showed 97% objective response rate in Phase II, with 51% complete histological clearance. 
  - Torii filed NDA for YCANTH in Japan, targeting 1.6M molluscum patients. 

**【CFO Financial Update】**
- **Funding**: Raised $42M in November 2024 equity offering, bringing cash to $46.3M as of Q4. Secured covenant waivers with OrbiMed through Q1 2025. 
- **Revenue**: Full year 2024 revenue $7.6M (vs $5.1M prior year), driven by YCANTH net product revenue ($6.6M vs $4.7M). 
- **Expenses**: R&D down 45% YoY to $11.8M; SG&A down 14% to $58.8M due to commercial restructuring. 
- **Losses**: GAAP net loss $76.8M (1.48/share) vs $67M prior year; non-GAAP loss $64.6M. 
- **Debt**: $50M OrbiMed facility now requires monthly principal repayments, reclassified to current liabilities. 

**【Q&A Highlights】**
- **2025 Outlook**: Early Q1 momentum aligns with Q4 growth trajectory; pediatrician adoption expanding. 
- **VP-315 Pathway**: Minimal incremental R&D spend needed post-FDA feedback; full commercial rights retained. 
- **Generic Risk**: Robust IP portfolio; 503B compounding challenges resolved. 
- **Cash Position**: Current cash sufficient for 2025 operations if Torii milestone ($8M) or warrant exercises materialize. 


Actual								-3.9	-3.8	-4.2	-5.2	-0.4	-4.3	-4.7	-3.5	-3.1	-3.7	0	-1.4	-1.5	-2.4	-5.4	-5.3	-4.4	-3.7	-4.9	-2.4	-1	0.02	-0.57
Forecast								-3.8	-4.5	-4.3	-4.175	-3.475	-4.14	-5.1	-4.975	-3.34	-3.2	-1.05	-1.9135	-1.9047	-2.1016	-3.6134	-5.62	-4.4695	-4.1385	-3.763	-2.5	-1.2617	-0.9	-0.732
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2.63%	+15.56%	+2.33%	-24.55%	+88.49%	-3.86%	+7.84%	+29.65%	+7.19%	-15.63%	+100.00%	+26.84%	+21.25%	-14.20%	-49.44%	+5.69%	+1.55%	+10.60%	-30.22%	+4.00%	+20.74%	+102.22%	+22.13%

Actual	--	--	--	--	--	--	--	0	0	0	0	12.00M	0	0	0	431.00K	214.00K	8.32M	68.00K	37.00K	182.00K	2.92M	1.99M	3.83M	5.18M	-1.78M	344.00K	3.44M	12.70M	5.09M
Forecast	--	--	--	--	--	--	--	0	0	0	0	0	200.00K	0	0	332.40K	312.50K	4.33M	312.50K	322.00K	57.60K	454.07K	975.25K	2.81M	4.58M	5.26M	1.04M	2.54M	4.27M	4.52M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	0.00%	0.00%	+29.66%	-31.52%	+92.14%	-78.24%	-88.51%	+215.97%	+542.41%	+103.85%	+36.29%	+12.96%	-133.85%	-66.97%	+35.65%	+197.70%	+12.65%

VRCA

VRCA fundamentals

VRCA Q4 2025 Earnings

Earnings Call

You can ask Aime

VRCA

VRCA fundamentals

VRCA Q4 2025 Earnings

Earnings Call

VRCA Earnings Call Summary for Q4/20258:30 AM on Mar 11, 2026

VRCA Earnings Call Summary for Q2/20254:30 PM on Aug 12, 2025

VRCA Earnings Call Summary for Q1/20254:30 PM on May 13, 2025

VRCA Earnings Call Summary for Q4/20244:30 PM on Mar 11, 2025

VRCA Earnings Call Summary for Q3/2024 Apr 3, 2026

You can ask Aime